Literature DB >> 33154553

Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China.

Lin Zhu1,2, Chun-Yuan Zhang1,2, Dong-Ping Li3, Hu-Biao Chen4, Jiang Ma1,2, Hong Gao3, Yang Ye2,5, Ji-Yao Wang3, Peter P Fu6, Ge Lin7,8.   

Abstract

Herbs and dietary supplement-induced liver injury (HILI) is the leading cause of drug-induced liver injury in China. Among different hepatotoxic herbs, the pyrrolizidine alkaloid (PA)-producing herb Gynura japonica contributes significantly to HILI by inducing hepatic sinusoidal obstruction syndrome (HSOS), a liver disorder characterized by hepatomegaly, hyperbilirubinemia, and ascites. In China, G. japonica has been used as one of the plant species for Tu-San-Qi and is often misused with non-PA-producing Tu-San-Qi (Sedum aizoon) or even San-Qi (Panax notoginseng) for self-medication. It has been reported that over 50% of HSOS cases are caused by the intake of PA-producing G. japonica. In this review, we provide comprehensive information to distinguish these Tu-San-Qi-related herbal plant species in terms of plant/medicinal part morphologies, medicinal indications, and chemical profiles. Approximately 2156 Tu-San-Qi-associated HSOS cases reported in China from 1980 to 2019 are systematically reviewed in terms of their clinical manifestation, diagnostic workups, therapeutic interventions, and outcomes. In addition, based on the application of our developed mechanism-based biomarker of PA exposure, our clinical findings on the definitive diagnosis of 58 PA-producing Tu-San-Qi-induced HSOS patients are also elaborated. Therefore, this review article provides the first comprehensive report on 2214 PA-producing Tu-San-Qi (G. japonica)-induced HSOS cases in China, and the information presented will improve public awareness of the significant incidence of PA-producing Tu-San-Qi (G. japonica)-induced HSOS and facilitate future prevention and better clinical management of this severe HILI.
© 2020. CPS and SIMM.

Entities:  

Keywords:  Gynura japonica; Tu-San-Qi; hepatic sinusoidal obstruction syndrome; herb-induced liver injury; pyrrolizidine alkaloids

Mesh:

Substances:

Year:  2020        PMID: 33154553      PMCID: PMC8285480          DOI: 10.1038/s41401-020-00553-9

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  43 in total

Review 1.  Drug-related hepatotoxicity.

Authors:  Victor J Navarro; John R Senior
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

2.  ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.

Authors:  Naga P Chalasani; Paul H Hayashi; Herbert L Bonkovsky; Victor J Navarro; William M Lee; Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

Review 3.  Plant sources of hepatotoxic pyrrolizidine alkaloids.

Authors:  L W Smith; C C Culvenor
Journal:  J Nat Prod       Date:  1981 Mar-Apr       Impact factor: 4.050

Review 4.  Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.

Authors:  Ge Lin; Ji Yao Wang; Na Li; Mi Li; Hong Gao; Yuan Ji; Fan Zhang; Huali Wang; Yan Zhou; Yang Ye; Hong Xi Xu; Jiang Zheng
Journal:  J Hepatol       Date:  2010-09-22       Impact factor: 25.083

5.  Incidence and Etiology of Drug-Induced Liver Injury in Mainland China.

Authors:  Tao Shen; Yingxia Liu; Jia Shang; Qing Xie; Jun Li; Ming Yan; Jianming Xu; Junqi Niu; Jiajun Liu; Paul B Watkins; Guruprasad P Aithal; Raúl J Andrade; Xiaoguang Dou; Lvfeng Yao; Fangfang Lv; Qi Wang; Yongguo Li; Xinmin Zhou; Yuexin Zhang; Peilan Zong; Bin Wan; Zhengsheng Zou; Dongliang Yang; Yuqiang Nie; Dongliang Li; Yuya Wang; Xi'an Han; Hui Zhuang; Yimin Mao; Chengwei Chen
Journal:  Gastroenterology       Date:  2019-02-08       Impact factor: 22.682

Review 6.  Tusanqi and hepatic sinusoidal obstruction syndrome.

Authors:  Ji Yao Wang; Hong Gao
Journal:  J Dig Dis       Date:  2014-03       Impact factor: 2.325

Review 7.  Pyrrolizidine Alkaloids: Potential Role in the Etiology of Cancers, Pulmonary Hypertension, Congenital Anomalies, and Liver Disease.

Authors:  John A Edgar; Russell J Molyneux; Steven M Colegate
Journal:  Chem Res Toxicol       Date:  2014-12-26       Impact factor: 3.739

Review 8.  Pyrrolizidine alkaloids--genotoxicity, metabolism enzymes, metabolic activation, and mechanisms.

Authors:  Peter P Fu; Qingsu Xia; Ge Lin; Ming W Chou
Journal:  Drug Metab Rev       Date:  2004-02       Impact factor: 4.518

Review 9.  Sinusoidal obstruction syndrome.

Authors:  Dominique-Charles Valla; Dominique Cazals-Hatem
Journal:  Clin Res Hepatol Gastroenterol       Date:  2016-03-30       Impact factor: 2.947

10.  Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.

Authors:  Yan Wang; Dan Qiao; Ya Li; Feng Xu
Journal:  BMC Gastroenterol       Date:  2018-10-26       Impact factor: 3.067

View more
  11 in total

1.  Fasting augments pyrrolizidine alkaloid-induced hepatotoxicity.

Authors:  Jiang Ma; Chunyuan Zhang; Yisheng He; Xinmeng Chen; Ge Lin
Journal:  Arch Toxicol       Date:  2021-11-18       Impact factor: 5.153

2.  Developing urinary pyrrole-amino acid adducts as non-invasive biomarkers for identifying pyrrolizidine alkaloids-induced liver injury in human.

Authors:  Lin Zhu; Chunyuan Zhang; Wei Zhang; Qingsu Xia; Jiang Ma; Xin He; Yisheng He; Peter P Fu; Wei Jia; Yuzheng Zhuge; Ge Lin
Journal:  Arch Toxicol       Date:  2021-08-14       Impact factor: 6.168

3.  Correlation Investigation between Pyrrole-DNA and Pyrrole-Protein Adducts in Male ICR Mice Exposed to Retrorsine, a Hepatotoxic Pyrrolizidine Alkaloid.

Authors:  Lin Zhu; Junyi Xue; Yisheng He; Qingsu Xia; Peter P Fu; Ge Lin
Journal:  Toxins (Basel)       Date:  2022-05-28       Impact factor: 5.075

4.  Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.

Authors:  Xuan Wang; Wei Zhang; Ming Zhang; Feng Zhang; Jiangqiang Xiao; Qin Yin; Hao Han; Taishun Li; Ge Lin; Yuzheng Zhuge
Journal:  Hepatol Int       Date:  2022-01-12       Impact factor: 9.029

5.  The key role of gut-liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity.

Authors:  Yisheng He; Jiang Ma; Xiaoyu Fan; Liang Ding; Xinxin Ding; Qing-Yu Zhang; Ge Lin
Journal:  Acta Pharm Sin B       Date:  2021-07-21       Impact factor: 11.413

6.  Pyrrolizidine Alkaloid-Induced Hepatotoxicity Associated with the Formation of Reactive Metabolite-Derived Pyrrole-Protein Adducts.

Authors:  Jiang Ma; Mi Li; Na Li; Wood Yee Chan; Ge Lin
Journal:  Toxins (Basel)       Date:  2021-10-13       Impact factor: 4.546

7.  Sorting out the plants responsible for a contamination with pyrrolizidine alkaloids in spice seeds by means of LC-MS/MS and DNA barcoding: Proof of principle with cumin and anise spice seeds.

Authors:  Marie Willocx; Iris Van der Beeten; Pieter Asselman; Lynn Delgat; Wim Baert; Steven B Janssens; Frederik Leliaert; Jean-François Picron; Celine Vanhee
Journal:  Food Chem (Oxf)       Date:  2022-01-01

8.  Liquorice Extract and 18β-Glycyrrhetinic Acid Protect Against Experimental Pyrrolizidine Alkaloid-Induced Hepatotoxicity in Rats Through Inhibiting Cytochrome P450-Mediated Metabolic Activation.

Authors:  Zhangting Wang; Jiang Ma; Sheng Yao; Yisheng He; Kai-Kei Miu; Qingsu Xia; Peter P Fu; Yang Ye; Ge Lin
Journal:  Front Pharmacol       Date:  2022-03-16       Impact factor: 5.810

9.  Quantification of Usaramine and its N-Oxide Metabolite in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Feifei Lin; Yan Ma; Anni Pan; Yang Ye; Jia Liu
Journal:  J Anal Toxicol       Date:  2022-05-20       Impact factor: 3.220

10.  Investigation of Gynura segetum root extract (GSrE) induced hepatotoxicity based on metabolomic signatures and microbial community profiling in rats.

Authors:  Xinyi Gu; Shuwei Li; Mengna Lu; Ying Li; Qixue Wang; Long Chen; Yiqun Jia; Shan Cao; Ting Zhang; Mingmei Zhou; Xiaojun Gou
Journal:  Front Microbiol       Date:  2022-08-09       Impact factor: 6.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.